Concepts, consequences, and implications of theranosis

Seminars in Nuclear Medicine

Volumn 42, Issue 3, 2012, Pages 147-150

  Denardo, Gerald L ^a,b   Denardo, Sally J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CYTOTOXIC AGENT; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; INDIUM; IODINE 131; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB;

ARTICLE; CANCER CELL; CELL SPECIFICITY; GLYCOLYSIS; HYPERTHYROIDISM; MOLECULAR IMAGING; NONHODGKIN LYMPHOMA; PATIENT CARE; PHENOTYPE; PROTEOMICS; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; THYROID CANCER; UPREGULATION;

EID: 84859335863     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2011.12.003     Document Type: Review

References (40)

1. S.M. Ali, W.P. Carney, F.J. Esteva Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer Cancer 113 2008 1294 1301
2. G.L. DeNardo The conundrum of personalized cancer management, drug development and economics Cancer Biother Radiopharm 22 2007 719 721
3. A.D. Nunn Molecular imaging and personalized medicine: An uncertain future Cancer Biother Radiopharm 22 2007 722 739
4. 131 I-tositumomab therapy as initial treatment for follicular lymphoma N Engl J Med 352 2005 441 449
5. M.S. Kaminski, J. Estes, K.R. Zasadny Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Update results and long-term follow-up of the University of Michigan experience Blood 96 2000 1259 1266
6. T.E. Witzig, L.I. Gordon, F. Cabanillas Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 20 2002 2453 2463
7. T.E. Witzig, I.W. Flinn, L.I. Gordon Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol 20 2002 3262 3269
8. L.I. Gordon, T. Witzig, A. Molina Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma Clin Lymphoma 5 2004 98 101
9. C. Emmanouilides Radioimmunotherapy for non-Hodgkin's lymphoma: Historical perspective and current status J Clin Exp Hematop 47 2007 43 60
10. O.W. Press Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas J Clin Oncol 26 2008 5147 5150
11. 90 Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma Cancer Biother Radiopharm 20 2005 185 188
12. J.P. Leonard, R.R. Furman, J. Ruan New developments in immunotherapy for non-Hodgkin's lymphoma Curr Oncol Rep 7 2005 364 371
13. S.J. Horning, A. Younes, V. Jain Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B cell lymphoma, progressive after rituximab J Clin Oncol 23 2005 712 719
14. C. Emmanouilides, T.E. Witzig, G.A. Wiseman Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma Cancer Biother Radiopharm 22 2007 684 691
15. H. Gomez, L. Mas, L. Casanova Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity J Clin Oncol 16 1998 2352 2358
16. M. MacManus, R.T. Hoppe Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University J Clin Oncol 14 1996 1282 1290
17. R.I. Fisher, E.R. Gaynor, S. Dahlberg Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 1993 1002 1006
18. M. Ghielmini, S.F. Schmitz, S.B. Cogliatti Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule Blood 103 2004 4416 4423
19. M.S. Kaminski, A.D. Zelenetz, O.W. Press Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 19 2001 3918 3928
20. V. Lewington Development of 131I-tositumomab Semin Oncol 32 Suppl 1 2005 S50 S56
21. R.I. Fisher, M.S. Kaminski, R.L. Wahl Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas J Clin Oncol 23 2005 7565 7573
22. A.J. Davies, A.Z. Rohatiner, S. Howell Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma J Clin Oncol 22 2004 1469 1479
23. R.I. Fisher, R.B. Jones, V.T. DeVita Natural history of malignant lymphomas with divergent histologies at staging evaluation Cancer 47 1981 2022 2025
24. P.W. Johnson, A.Z. Rohatiner, J.S. Whelan Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center J Clin Oncol 13 1995 140 147
25. C.S. Portlack Should radioimmunotherapy be an initial treatment option in advanced-stage follicular lymphoma? Nat Clin Pract Oncol 2 2005 346 347
26. P.F. Ferrucci, A. Vanazzi, C.M. Grana High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas Br J Haematol 139 2007 590 599
27. O.W. Press, J.M. Unger, R.M. Braziel A phase II trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911 Blood 102 2003 1606 1612
28. O.W. Press, J.M. Unger, R.M. Braziel Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911 J Clin Oncol 24 2006 4143 4149
29. F. Morschhauser, J. Radford, A. Van Hoof Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma J Clin Oncol 26 2008 5156 5164
30. 131 I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma J Clin Oncol 16 1998 3246 3256
31. M.S. Kaminski, J.A. Radford, S.A. Gregory Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab J Clin Oncol 23 2005 7985 7993
32. 131 I-Lym-1 antibody Cancer Biother Radiopharm 13 1998 239 254
33. G.L. DeNardo, J. Schlom, D.J. Buchsbaum Rationales, evidence and design considerations in fractionated radioimmunotherapy Cancer 94 2002 1332 1348
34. I. Zafir-Lavie, Y. Michaeli, Y. Reiter Novel antibodies as anticancer agents Oncogene 26 2007 3714 3733
35. G.L. DeNardo, G.R. Mirick, S. Hok Molecular specific and cell selective cytotoxicity induced by a novel synthetic HLA-DR antibody mimic for lymphoma and leukemia Int J Oncol 34 2009 511 516
36. S.M. Seidlin, L.D. Marinelli, E. Oshry Radioactive iodine therapy: Effect on functioning metastases of adenocarcinoma of the thyroid CA Cancer J Clin 40 1990 299 317
37. D. Mankoff A definition of molecular imaging J Nucl Med 48 2007 18N
38. M.E. Juweid, S. Stroobants, O.S. Hoekstra Use of positron emission tomography for response assessment of lymphoma: Consensus of the imaging subcommittee of international harmonization project in lymphoma J Clin Oncol 25 2007 571 578
39. L.K. Shankar, J.M. Hoffman, S. Bacharach Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials J Nucl Med 47 2006 1059 1066
40. M. Cremonesi, M. Ferrari, L. Bodei Dosimetry in peptide receptor therapy: A review J Nucl Med 47 2006 1467 1475